This study will evaluate the effectiveness of SIGHT as a clinical support system to prompt provider/patient discussion and shared decision making regarding the need for genetic testing in the form of a chromosomal microarray. Identifying patients at high predicted probability of needing a test in clinical settings will be examined to determine if it decreases the duration of time to testing and increases diagnostic yield. SIGHT requires only data already collected in routine clinical encounters and is calculated prior to a clinical visit at VUMC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
1,000
Among patients surpassing a 0.30 probability threshold that have a scheduled visit to pediatric primary care at VUMC, 500 will be randomized to the intervention and a SIGHT-prompted provider message will be generated.
Vanderbilt University Medical
Nashville, Tennessee, United States
Number of Diagnoses in the intervention arm compared to the control arm
Number of patients diagnosed via a Chromosomal Microarray.
Time frame: 2 years
Time to test
Duration of time to genetic testing. Time to event, measured from the initial patient visit to the time genetic testing is conducted.
Time frame: 2 years
Abnormal CMA
Number of patients flagged by SIGHT who's CMA result returned abnormal but in the absence of diagnostic findings.
Time frame: 2 years
Rate of genetic testing
Rates of genetic testing ordered by providers after a pediatric visit.
Time frame: 2 years
Diagnosis via any test (molecular confirmation)
Number of patients flagged by SIGHT who receive a diagnosis via any molecular test.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.